Maintaining Low BCR-ABL Signaling Output to Restrict CML Progression and Enable Persistence

Current Hematologic Malignancy Reports - United States
doi 10.1007/s11899-013-0196-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Adherence to BCR-ABL Inhibitors: Issues for CML Therapy

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2012English

Genomic Mechanisms of P210 BCR-ABL Signaling

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2004English

Inhibition of the BCR-Abl Tyrosine Kinase as a Therapeutic Strategy for CML

Oncogene
Cancer ResearchGeneticsMolecular Biology
2002English

MT1-MMP as a Downstream Target of BCR-ABL/ABL Interactor 1 Signaling: Polarized Distribution and Involvement in BCR-ABL-stimulated Leukemic Cell Migration

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2007English

Coexistence of AML1/RUNX1 and BCR-ABL Point Mutations in an Imatinib-Resistant Form of CML

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

A Multiple Reaction Monitoring (MRM) Method to Detect BCR-Abl Kinase Activity in CML Using a Peptide Biosensor

PLoS ONE
Multidisciplinary
2013English

BCR-ABL Tyrosine Kinase

Science-Business eXchange
2012English

Multidomain Targeting of BCR-Abl by Disruption of Oligomerization and Tyrosine Kinase Inhibition: Toward Eradication of CML

Molecular Pharmaceutics
Drug DiscoveryMolecular MedicinePharmaceutical Science
2013English

Protein Kinase CKIIa Interacts With the BCR Moiety of BCR/Abl and Mediates Proliferation of BCR/Abl-Expressing Cells

Oncogene
Cancer ResearchGeneticsMolecular Biology
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy